TOKYO, Apr 16 (Pulse News Wire) – RIBOMIC Inc. (4591.T) entered into a joint research agreement with SK Plasma Co., Ltd.
To develop aptamer-drug complexes. Under the agreement, SK Plasma will fund Ribomic's research progress, though specific financial details remain undisclosed. Ribomic specializes in developing aptamers for pharmaceutical applications using its proprietary RiboART® system. The collaboration leverages SK Plasma’s expertise in plasma-derived drug development, manufacturing, and sales.
Both companies aim to create novel compounds with enhanced properties by combining SK Plasma’s drugs with Ribomic’s aptamers. Established on March 05, 2015, SK Plasma operates out of 310 Pangyo-ro, Bundang, South Korea, and has a capital of KRW 9,876,683,500. The joint venture does not involve any capital, personal, or transactional relationships between the two firms. Regarding future outlook, Ribomic plans to incorporate the impact of this agreement into its fiscal 2027 March quarter earnings forecast.
🟢 Confidence: High AI-translated content.